Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427030 | 0.91 | SLC6A9 (0.72) | SLC6A9KCNH2NR1I2CACNA1B | |
| SCHEMBL4426822 | 0.90 | SLC6A9 (0.78) | SLC6A9KCNH2 | |
| SCHEMBL4422115 | 0.90 | SLC6A9 (0.79) | SLC6A9KCNH2 | |
| SCHEMBL4432880 | 0.90 | SLC6A9 (0.79) | SLC6A9KCNH2 | |
| SCHEMBL4422319 | 0.87 | SLC6A9 (1.00) | SLC6A9KCNH2 | |
| SCHEMBL3921253 | 0.87 | SLC6A9 (0.73) | SLC6A9KCNH2NR1I2CACNA1B | |
| SCHEMBL4424944 | 0.87 | SLC6A9 (0.75) | SLC6A9KCNH2 | |
| SCHEMBL4435392 | 0.86 | SLC6A9 (0.92) | SLC6A9KCNH2 | |
| SCHEMBL4425747 | 0.86 | SLC6A9 (0.78) | SLC6A9KCNH2NR1I2CACNA1B | |
| SCHEMBL4424387 | 0.86 | SLC6A9 (0.79) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | SLC6A9 2325/4885KCNH2 628/4885NR1I2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.